Endocrine Abstracts

Introduction: Glucose metabolism impairment is a common complication of acromegaly. Somatostatin analogs (SSAs) are used as both first and second line treatment. The effect of SSAs on glucose metabolism in acromegaly is still debated.Aim: To address the following questions: 1) do SSAs affect glucose metabolism? 2) does the effect correlate with disease control? 3) do different SSAs – Lanreotide (LAN) and octreotide LAR (OCT) – affect metabolism...

Context: Significant uncertainty exists about the diagnostic accuracy of ultrasonographic (US) features used to predict the risk of thyroid cancer in the pediatric population. Moreover, there are not specific indications for thyroid nodule evaluation in patients during the transition age.Objective: The meta-analysis aimed to address the following question: which thyroid nodule US features have the highest accuracy in predicting malignancy in the transiti...

Introduction: Glucose metabolism impairment is a common complication of acromegaly. Pegvisomant (PEG) is used as second-line medical treatment in acromegaly. Data from literature suggest a positive effect of PEG on glucose metabolism but a meta-analysis has never been performed.Aim: To address the following questions: i) does PEG affect glucose metabolism? ii) does the effect correlate with disease control?Methods: We performed a m...